Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | (1) | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| MorphoSys AG (PK) | MPSYF | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 71.38 | 16:10:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 71.38 | 71.38 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 20.15 - 72.71 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 71.38 | USD |
MorphoSys AG (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.65B | 22.94M | - | 238.28M | -189.73M | -5.04 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
MorphoSys (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MPSYF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 72.71 | 72.71 | 71.38 | 71.77 | 182 | -1.33 | -1.83% |
| 6 Months | 20.15 | 72.71 | 20.15 | 61.51 | 23,219 | 51.23 | 254.24% |
| 1 Year | 25.79 | 72.71 | 20.15 | 60.63 | 18,112 | 45.59 | 176.77% |
| 3 Years | 87.80 | 87.80 | 13.84 | 59.75 | 9,646 | -16.42 | -18.70% |
| 5 Years | 104.505 | 142.75 | 13.84 | 76.01 | 8,102 | -33.13 | -31.70% |
MorphoSys (PK) Description
| MorphoSys developed HuCAL, the most successful antibody library technology in the pharmaceutical industry. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human healthcare. Together with its partners in the pharmaceutical industry, MorphoSys has built a therapeutic pipeline of drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With its ongoing commitment to new antibody technology and drug development, MorphoSys is focused on making the healthcare products of tomorrow. Over 70 therapeutic antibody programs based on the company's technologies are currently in development, of which 20 are in clinical trials. The company's most advanced proprietary program is MOR103, a first-in-class antibody against GM-CSF for the treatment of rheumatoid arthritis and multiple sclerosis. MOR103 is part of MorphoSys's collaboration with GlaxoSmithKline. Other proprietary clinical programs include MOR208 and MOR202, both for the treatment of cancer. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. |
